SR9238 is primarily studied for its potential therapeutic applications, particularly in the context of metabolic diseases and cancer. It functions as an inverse agonist of liver X receptors (LXRs), which play a role in regulating cholesterol and lipid metabolism. By inhibiting LXR activity, SR9238 has shown promise in reducing lipid accumulation in the liver, making it a candidate for treating non-alcoholic fatty liver disease (NAFLD) and other metabolic disorders. Additionally, its ability to modulate LXR pathways has sparked interest in its potential use in cancer research, as LXRs are involved in tumor growth and progression. Early studies suggest that SR9238 may help suppress tumor development and improve the efficacy of existing cancer therapies. However, further research is needed to fully understand its mechanisms and validate its clinical applications.